Regeneron Pharmaceuticals ( (REGN) ) has released its Q3 earnings. Here is a breakdown of the information Regeneron Pharmaceuticals presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes innovative medicines for serious diseases, utilizing proprietary technologies to advance drug development across various therapeutic areas. In its third quarter of 2025, Regeneron reported a 1% increase in revenues, reaching $3.75 billion, with notable growth in Dupixent sales and new FDA approvals for key treatments. The company’s financial performance was marked by a 9% increase in GAAP net income, although non-GAAP net income saw a decline. Regeneron highlighted strategic advancements, including FDA approvals for Libtayo and Evkeeza, and promising clinical trial results in several therapeutic areas. Looking ahead, Regeneron remains focused on advancing its late-stage pipeline and maintaining solid financial performance, with continued investments in innovation and shareholder value.